CONICET | Buscador de Institutos y Recursos Humanos

Arterial hypertension (AH) determines changes in the cardiac structure and associated geometric alterations such as left ventricular hypertrophy (LVH). On the other hand, ventricular remodeling (VR) responds to changes in cardiac size and conformation, which can lead to impaired ventricular function (VF). In this regard, endogenous molecules with therapeutic potentials, such as anandamide (AEA), are investigated. AEA exert beneficial properties at the cardiovascular level but, unfortunately, with many secondary and/or adverse effects, which determined its rejection in subsequent clinical trials. Of interest, new technologies -including nano-structured polymers- are opening up new therapeutic alternatives. In this regard, our laboratory has designed a new method to obtain an unprecedented nano-scaffold carrying the active principle AEA with which the present research work was carried out. Thus, our objective was to evaluate in spontaneously hypertensive rats (SHR) treated with nano-formulated AEA the possible hemodynamic, structural, cardiac functional changes, and inflammatory markers of interest. Male rats (N=10 per group, 250-300 g) normotensive (WKY) and SHR, treated or not with AEA nano-formulated in epsilon polycaprolactone (AEA/PCL, 5 mg/Kg, IP), 1 weekly dose for 4 weeks. Before and after the pharmacological protocol, we determined systolic blood pressure (SBP, CODA), body and heart weight, two-dimensional echocardiogram (Echo), ECG, and inflammatory markers. In addition, routine blood tests, weight and cardiac histology, ventricular size and wall size in the long and short axis were performed, according to Teichholz, to calculate VF, body surface area and ventricular mass index (VMI). AEA/PCL in SHR managed to reverse all the alterations observed in untreated SHR, such as the elevation of inflammatory markers (IL-1, IL-6, TNFα, high-sensitivity CRP and plasma Hsp70; p

enviar mensaje